Jaguar Health, Inc. (NASDAQ:JAGX) is set to announce third quarter earning results on Monday 16th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, JAGX to report 3Q20 loss of $ 0.11 per share from revenue of $ 7.80 million.
For the full year, analysts anticipate top line of $ 23.47 million, while looking forward to loss of $ 0.69 per share bottom line.
Previous Quarter Performance
Jaguar Health, Inc. recorded loss for the second quarter of $ 0.44 per share, from the revenue of $ 3.17 million. The consensus estimates are loss of $ 0.15 per share from $ 4.78 million in revenue. The bottom line results missed street analysts by $ 0.29 or 193.33 percent, at the same time, top line results fell short of analysts by $ 1.61 million or 33.68 percent.
Stock Performance
On Friday, shares of Jaguar Health, Inc. has traded high as $ 0.21 and has cracked $ 0.20 on the downward trend, reaching $ 0.20 with volume of 3.79 million shares.
According to the previous trading day, closing price of $ 0.20, representing a 10.53 % increase from the 52 week low of $ 0.19 and a 80.56 % decrease over the 52 week high of $ 1.08.
The company has a market capital of $ 11.34 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Jaguar Health, Inc. will be hosting a conference call at 8:30 AM eastern time on 16th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, 866-548-4713 U.S. or 323-794-2093 Toll Number, with passcode : 8490376 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website jaguar.health
Jaguar Health, Inc., a commercial stage natural-products pharmaceuticals company, focuses on developing gastrointestinal products for human prescription use and animals worldwide. The company, through its wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Its human health product pipelines include Mytesi, which is Phase II clinical trial for the treatment of cancer therapy-related diarrhea, as well as for the supportive care for inflammatory bowel disease; formulation of crofelemer that is Phase II clinical trial for the treatment of short bowel syndrome, congenital diarrheal disorders, and irritable bowel syndrome – diarrhea predominant diseases; and SB-300, a second-generation anti-secretory agent for multiple indications, including cholera.
